Nederlands tijdschrift voor geneeskunde
-
Ned Tijdschr Geneeskd · Feb 1993
Comparative Study[Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Evaluation of HA-1A treatment in patients with the sepsis syndrome. ⋯ HA-1A does not appear to be beneficial in critically ill patients with a longstanding sepsis syndrome, especially not if an intra-abdominal sepsis is apparent. Therefore, we decided not to use H-1A until additional data become available. Additional objective inclusion criteria are needed to improve the identification of the patient group that may benefit from treatment with HA-1A.